ライフサイエンスコーパス: C-type natriuretic peptide

1 s to DEA/NO, atrial natriuretic peptide, and C-type natriuretic peptide.

2 the B-type natriuretic peptide (BNP) and the C-type natriuretic peptide.

3 t of recent advances with a special focus on C-type natriuretic peptide.

4 of the Npr2 abolished protective effects of C-type natriuretic peptide, a ligand for Npr2, against d

5 Vosoritide is a biologic analogue of C-type natriuretic peptide, a potent stimulator of endoc

6 C-type natriuretic peptide activation of guanylyl cyclas

7 tic peptide acts primarily on the artery and C-type natriuretic peptide acts predominantly on the vei

8 rophy and pathologic calcification, and with C-type natriuretic peptide, an essential factor in endoc

9 om these vessels, the pattern of response to C-type natriuretic peptide and atrial natriuretic peptid

10 donors was mimicked by 2 cGMP analogues and C-type natriuretic peptide and blocked by a specific inh

11 racrine signaling by extracellular peptides (C-type natriuretic peptide and EGF receptor ligands) mai

12 r affinity for [125I]-DNP binding sites than C-type natriuretic peptide and the natriuretic peptide r

13 Atrial natriuretic peptide (ANP), C-type natriuretic peptide, and C-ANP-(4-23), a ligand f

14 pulmonary vasculature to atrial, B-type, and C-type natriuretic peptides (ANP, BNP, and CNP) during a

15 investigated the potential of uCNP (urinary C-type natriuretic peptide) as a biomarker for AKI.

16 Here, we focus on the cardioprotective CNP (C-type natriuretic peptide) as a novel antiarrhythmic pr

17 C-type natriuretic peptide attenuated CCh-induced contra

18 C-type natriuretic peptide binding to natriuretic peptid

19 CNP (C-type natriuretic peptide) can also regulate atrial ele

20 C-type natriuretic peptide (CNP) antagonizes FGFR3 downs

21 ions of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) are elaborated by membr

22 We have recently identified C-type natriuretic peptide (CNP) as an endothelium-deriv

23 C-type natriuretic peptide (CNP) binds the guanylyl cycl

24 C-type natriuretic peptide (CNP) fulfills a multimodal p

25 ently, CD-NP, a chimeric peptide composed of C-type natriuretic peptide (CNP) fused to the C-terminal

26 In epineurial arterioles, C-type natriuretic peptide (CNP) has properties consiste

27 C-type natriuretic peptide (CNP) has therapeutic potenti

28 te important roles for nitric oxide (NO) and C-type natriuretic peptide (CNP) in the regulation of ca

29 Both atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) increased the accumulat

30 C-type natriuretic peptide (CNP) is a fundamental endoth

31 C-type natriuretic peptide (CNP) is a member of the natr

32 C-type natriuretic peptide (CNP) is a new member of this

33 C-type natriuretic peptide (CNP) is a newly discovered f

34 C-type natriuretic peptide (CNP) is a vasodilator produc

35 C-type natriuretic peptide (CNP) is involved in the regu

36 minal pro-BNP (NT-proBNP), proBNP(1-108), or C-type natriuretic peptide (CNP) is not well understood.

37 We tested the hypothesis that C-type natriuretic peptide (CNP) mediates coronary vasod

38 he binding of atrial natriuretic peptide and C-type natriuretic peptide (CNP) to the guanylyl cyclase

39 be coimmunoprecipitated with Galpha(i), and C-type natriuretic peptide (CNP) treatment induced trans

40 domain of the mammalian receptor (GC-B) for C-type natriuretic peptide (CNP) was fused to the cataly

41 uced by atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP), activators of particul

42 ial-specific deletion of Nppc, which encodes C-type natriuretic peptide (CNP), and determined that th

43 zed for angiotensin-converting enzyme (ACE), C-type natriuretic peptide (CNP), and nitric oxide.

44 Activating mutations in the receptor for C-type natriuretic peptide (CNP), guanylyl cyclase B (GC

45 C-type natriuretic peptide (CNP), in contrast, caused ha

46 GMP signaling pathway composed of the ligand C-type natriuretic peptide (CNP), its receptor, the guan

47 r S-nitroso-N-acetylpenicillamine (SNAP) and C-type natriuretic peptide (CNP), reduced TNF-alpha-indu

48 t marked elevations of cyclic GMP induced by C-type natriuretic peptide (CNP), the ligand of GC-B, bl

49 istically, Musclin enhances the abundance of C-type natriuretic peptide (CNP), thereby promoting card

50 ngest candidate therapy employs an analog of C-type natriuretic peptide (CNP), which antagonizes the

51 receptor 2 (NPR2) in response to the agonist C-type natriuretic peptide (CNP).

52 vascular and antiproliferative properties of C-type natriuretic peptide (CNP).

53 rom GTP on binding its extracellular ligand, C-type natriuretic peptide (CNP).

54 s a single transmembrane receptor that binds C-type natriuretic peptide (CNP).

55 in the brains of postnatal animals is atrial C-type natriuretic peptide (CNP).

56 lase, respectively, by nitric oxide (NO) and C-type natriuretic peptide (CNP).

57 Neither did C-type natriuretic peptide (CNP, 10, 100, 500 or 1000 pm

58 Increased concentrations of C-type natriuretic peptide could contribute to venous po

59 alization approach using a derivative of the C-type natriuretic peptide (dCNP).

60 Later, levels of the NPR2 agonist C-type natriuretic peptide decrease in the follicle, and

61 C-type natriuretic peptide-dependent increases of guanyl

62 r B (NPR-B) stimulates long bone growth in a C-type natriuretic peptide-dependent manner.

63 ic peptides, atrial natriuretic peptide, and C-type natriuretic peptide evoked fluorescence resonance

64 inin-potentiating peptides originated from a C-type natriuretic peptide gene backbone; and 4) VEGF-F

65 markedly increased by natriuretic peptides (C-type natriuretic peptide >> atrial natriuretic peptide

66 muscle cells cultured from these vessels to C-type natriuretic peptide in comparison with atrial nat

67 C-type natriuretic peptide inhibited isoproterenol-stimu

68 CNP (C-type natriuretic peptide) inhibits myofibrogenesis and

69 ocytochemically localized atrial, brain, and C-type natriuretic peptide-like immunoreactivity (ANP-LI

70 L658F, Y708C, R776W, and G959A) bound (125)I-C-type natriuretic peptide on the surface of cells but f

71 clase B is the receptor for a small peptide (C-type natriuretic peptide) produced locally in many dif

72 In H69 cells, atrial and C-type natriuretic peptides stimulated production of cGM

73 l value) was more effective than 1 microM of c-type natriuretic peptide (three-fold increase in cycli

74 se with the discovery that administration of C-type natriuretic peptide to achondroplastic mice ameli

75 by daily injection of a recombinant form of C-type natriuretic peptide to post-natal pups for 18 day

76 ase in cyclic GMP in response to 1 microM of C-type natriuretic peptide vs. six-fold increase in cycl

77 In segments of intact saphenous vein, C-type natriuretic peptide was significantly more effect

78 the order ANP > brain natriuretic peptide >> C-type natriuretic peptide) was also similar to that of

79 Finally, C-type natriuretic peptide, which did not modulate TG ac